SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending due to news of a criminal investigation into Fed Chair Jerome Powell by the Department of Justice, which Powell claims is political retaliation aimed at pressuring the Fed to lower interest rates. This unprecedented situation has sparked widespread debate among the community, with many anticipating significant market volatility over concerns about Fed independence, while others view it as a potential buying opportunity.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU is trending due to its passionate community consistently building a permissionless brand with tangible real-world products like Kendu Spice and Kendu Energy, which sets it apart in the crypto space. The conversation highlights KENDU as a long-term conviction play, with community members focused on relentless building and organic growth across multiple blockchains.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is experiencing heightened volatility amidst significant geopolitical and domestic policy concerns stemming from former President Trump's actions. The community is abuzz with fears of a market downturn following a criminal probe targeting Fed Chair Powell, viewed as a direct threat to the Fed's independence, alongside international tensions around Venezuela and Greenland. Investors are sharply divided between those predicting a substantial market correction and others looking for dip-buying opportunities in the tech-heavy index.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital (APLD) is experiencing significant upward momentum driven by recent strong earnings, which validated its high-margin HPC lease economics. The community is buzzing with bullish sentiment, fueled by anticipation of imminent new hyperscaler lease announcements, a potential ChronoScale spin-off, and analyst target upgrades, including a notable $99 forecast. This surge is amplified by a prominent short-squeeze narrative, as retail and institutional investors alike recognize APLD's pivotal role in the expanding AI data center infrastructure market.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as community discussion centers on an unprecedented Department of Justice subpoena targeting Federal Reserve Chair Jerome Powell, igniting intense debate over the Fed's independence and political influence on monetary policy. This development, alongside recent foreign policy discussions, is drawing strong opinions from supporters who see the actions as justified, and critics who view them as political maneuvers impacting market sentiment.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is actively discussed as news circulates about a criminal investigation into Fed Chair Jerome Powell, which many in the community interpret as a significant challenge to Federal Reserve independence and a driver of currency debasement. This development, alongside ongoing geopolitical uncertainties and concerns about US debt, is fueling strong safe-haven demand for gold. While some anticipate further price surges, others highlight an overbought market and potential selling pressure from upcoming commodity index rebalancing.

The Ondo Foundation was founded in 2022 as an independently governed and nonprofit Cayman Islands Foundation Company with no beneficial owners. The Ondo Foundation assisted in the launch of the Ondo DAO, which deployed and currently governs Flux Finance, the first lending protocol supporting tokenized securities as collateral.  ONDO token holders are entrusted with shaping the future of the Ondo DAO so that it continues to pursue its mission to democratize access to institutional-grade finance. The Ondo DAO gives ONDO holders specific rights pertaining to Flux Finance, which is currently governed by the Ondo DAO.

Ondo

Ondo is trending due to recent positive developments, including the closure of a multi-year SEC investigation without charges and ongoing expansion of its tokenized US stocks and ETFs. While the community enthusiastically discusses its pivotal role in real-world asset tokenization and institutional affiliations, there are concurrent concerns regarding upcoming token unlocks and sluggish market performance.

Barrick Mining Corp. engages in the production and sale of gold, copper, and related activities. It also provides exploration and mining development. It operates through the following business segments: Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, Bulyanhulu, and Other Mines. The company was founded by Peter D. Munk in 1983 and is headquartered in Toronto, Canada.

Barrick Mining Corp.

Barrick Mining Corp

Barrick Mining Corp. is trending due to its recent announcement exploring an IPO for its North American gold assets and a significant settlement resolving disputes over its Mali gold mines, which restores operational control. The community is highly bullish, anticipating further upside, with many citing the company's strong financial position, increased dividends, and surging gold and copper prices as key drivers in the current commodity-friendly environment.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is currently a hot topic after activist investor Elliott Management disclosed a significant stake, aiming for strategic changes and backing a new CEO candidate as Calvin McDonald prepares to step down. This has ignited strong debate among the community, with many anticipating a significant rally driven by these leadership shifts and potential tariff-related news, while others point to ongoing selling pressure and valuation concerns. The stock's recent volatility is widely seen by some as a strategic buying opportunity ahead of these potential catalysts.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

DIA is trending due to immediate market reactions to geopolitical developments, specifically US actions in Venezuela, alongside discussions around potential credit card interest rate caps by the Trump administration. The community is sharply divided, with some viewing these events as bullish catalysts propelling the Dow to new highs, while others express significant concern about market stability and potential underlying vulnerabilities. This creates a broader conversation about the sustainability of the current rally amidst unpredictable policy shifts and external pressures.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Viking Therapeutics, Inc. (VKTX) Outperforms Broader Market: What You Need to Know

Viking Therapeutics, Inc. (VKTX) reached $31.99 at the closing of the latest trading day, reflecting a +1.07% change compared to its last close.

VKTX Completes Enrollment in Phase I Maintenance Study of Obesity Drug

Viking Therapeutics completes enrollment in a phase I maintenance study of VK2735, testing flexible oral and injectable dosing after initial weight loss in obese adults.

Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet

Based on the average brokerage recommendation (ABR), Viking Therapeutics (VKTX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Here's How Much $100 Invested In Viking Therapeutics 10 Years Ago Would Be Worth Today

Can the US Launch of NVO's Wegovy Pill Reignite Momentum in 2026?

Novo Nordisk shares jump after the U.S. launch of its FDA-approved Wegovy pill, giving the first oral GLP-1 weight-loss drug a chance to revive 2026 momentum.

Viking Therapeutics (NASDAQ:VKTX) CFO Greg Zante Sells 57,661 Shares

Viking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) CFO Greg Zante sold 57,661 shares of the company's stock in a transaction on Monday, January 5th. The stock was sold at an average price of...

<ul class="summary-bullets"><li>Regulatory filings showed share sales by Viking’s CEO, CFO and COO on Monday.</li><li>Novo Nordisk announced oral Wegovy pricing starting at $149 a month in the U.S.</li><li>Viking’s lead obesity drug VK2735 is still in Phase 3 clinical trials.</li></ul>Shares of Viking Therapeutics Inc. fell sharply on Monday, logging their worst day in more than four months, after regulatory filings showed significant share sales by the company’s top executives.&nbsp;The stock fell 9.3% to $32.14 in Monday’s regular session before paring some losses with a slight after-hours gain.According to the company’s filings on&nbsp;Monday, Brian Lian, Viking’s president and chief executive officer, sold 233,409 shares, stock worth about $7.7 million. On the same day, Greg Zante, the company’s chief financial officer, sold 57,661 shares valued at roughly $1.9 million, while Marianna Mancini, Viking’s chief operating officer, sold 57,661 shares, also worth about $1.9 million.<h2 class="st-heading-2">Novo’s Wegovy Pricing Adds Competitive Pressure</h2>The insider selling came as investors digested a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-wegovy-pill-price-149-month-retail-tells-shorts-time-to-give-up/cmxMZLwR4bo">major pricing move by Novo Nordisk</a>, which announced that U.S. customers can obtain the oral version of Wegovy starting at $149 per month. Novo said the 1.5 mg and 4 mg doses would be available to self-paying customers at that price beginning Monday, although the cost of the 4 mg dose will rise to $199 per month from April 15. The company added that higher 9 mg and 25 mg doses are priced at $299 per month, with no promotional offers.Novo also said customers with commercial insurance could pay as little as $25 per month for the oral pill. The announcement followed the FDA approval of oral Wegovy, making it the first oral GLP-1 drug approved for weight loss.<h2 class="st-heading-2">Viking’s Obesity Program</h2>Viking's lead obesity candidate, VK2735, is a dual GLP-1/GIP receptor agonist being developed in both subcutaneous and oral formulations. In November, Viking said it finished enrolling patients ahead of schedule in its Phase 3 Vanquish-1 trial, which is testing a once-weekly injection of VK2735 over 78 weeks in about 4,650 adults who are obese or overweight and have at least one weight-related health condition.The primary endpoint of the study is to measure the change in body weight relative to placebo, while also tracking the proportion of patients who achieve 5%, 10%, 15%, and 20% weight loss. Viking is also running a second Phase 3 trial, Vanquish-2, in overweight or obese patients with type 2 diabetes, with enrollment expected to finish in the first quarter of 2026. Earlier Phase 2 results showed patients lost up to 14.7% of their body weight in 13 weeks, which Viking said met its primary and secondary endpoints.<h2 class="st-heading-2">Wall Street Backs Viking</h2>In October, Canaccord initiated coverage of Viking Therapeutics with a ‘Buy’ rating and a $106 price target, calling Viking “a leader in the obesity drug development space.” The firm expects readouts from Viking’s two Phase 3 trials in 2027 and mid-2028, respectively, and pointed to what he described as “strong” Phase 2 efficacy data from the oral version of VK2735 reported in August. He added that Canaccord believes VK2735 could differentiate on “multiple fronts.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for Viking was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/vktx_ss_png_ef1044304f.webp" alt="vktx ss.png" width="972" height="147"><figcaption>VKTX sentiment and message volume as of January 5| Source: Stocktwits</figcaption></figure>One user said&nbsp;they would be a “buyer if this comes down to the mid-20s. Already have a position but would love to add more at a discount.”<stembedurl>https://stocktwits.com/T0THEM00NN/message/640902717</stembedurl>Another user pointed out that the insider selling “kills some buyout chances in near future.”<stembedurl>https://stocktwits.com/GreenHawkz/message/640900403</stembedurl><a href="https://stocktwits.com/symbol/VKTX">Viking’s stock</a> has declined 25% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a person holds a smartphone displaying the logo of Viking Therapeutics on July 19, 2025. (Photo illustration by Cheng Xin/Getty Images)

Viking Therapeutics Stock Suffers Worst Day In Over 4 Months As Top Execs Dump Shares — Novo’s $149 Wegovy Move Looms

Novo’s pricing applies to lower-dose oral Wegovy, with higher doses set at higher monthly prices.

Equity

Viking Therapeutics (NASDAQ:VKTX) CFO Sells $1,897,046.90 in Stock

Viking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) CFO Greg Zante sold 57,661 shares of the stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $32.90...

Marianna Mancini Sells 57,661 Shares of Viking Therapeutics (NASDAQ:VKTX) Stock

Viking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) COO Marianna Mancini sold 57,661 shares of the stock in a transaction on Monday, January 5th. The stock was sold at an average price of...

Insider Selling: Viking Therapeutics (NASDAQ:VKTX) CEO Sells 233,409 Shares of Stock

Viking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) CEO Brian Lian sold 233,409 shares of Viking Therapeutics stock in a transaction that occurred on Monday, January 5th. The shares were sold...

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Yes — Rates Move Meaningfully Lower

Short-Term Dip, No Lasting Impact

No — Mostly Political Noise

Other – Comment Below

President Trump says he’s directing $200 billion into mortgage bond purchases to bring down rates and improve housing affordability. With questions around execution, authority, and real market impact, do you think this move will actually lower mortgage rates in 2026?

Will Trump’s Mortgage Bond Plan Actually Lower Rates in 2026?

VKTX
Viking Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest VKTX News

VKTXViking Therapeutics Inc